Pharmacological, Toxicological and Dose-Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium Difficile Associated Infection (CDI).

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.01904-18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium Difficile Infection

Frontiers in Microbiology
Microbiology
2018English

Prevention and Treatment of Clostridium Difficile Infection

Geriatric Care
2017English

Expanding the Armamentarium for the Treatment of Clostridium Difficile Infection

The Lancet Infectious Diseases
Infectious Diseases
2017English

The CDI-DaySyms: Content Development of a New Patient-Reported Outcome (PRO) Questionnaire for Symptoms of Clostridium Difficile Infection

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pathophysiology, Diagnosis and Treatment of Clostridium Difficile Infection.

Keio Journal of Medicine
Medicine
1999English

Vancomycin Enema in the Treatment of Clostridium Difficile Infection

Surgical Infections
SurgeryInfectious DiseasesMicrobiology
2019English

The Difficile in Clostridium Difficile Infection

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2018English

Calprotectin and Lactoferrin Faecal Levels in Patients With Clostridium Difficile Infection (CDI): A Prospective Cohort Study

PLoS ONE
Multidisciplinary
2014English

Clostridium Difficile Infection

Nature Reviews Disease Primers
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy